logo
logo

Iron Path Capital-Backed Puretech Scientific Completes Acquisition Of Glycolic Acid Business From The Chemours Company

Aug 01, 2023•about 2 years ago

Acquiring Company

PureTech Scientific

Acquired Company

Glycolic Acid Business

BelleBiotechnologyManufacturing

Description

PureTech Scientific LLC today announced the completion of its acquisition of the Glycolic Acid business from The Chemours Company (NYSE: CC) for $137 million in cash, making PureTech Scientific a global leader in the organic synthesis of ultra-high purity alpha hydroxy acids for the Life Sciences and Specialty Chemical industries. PureTech Scientific was founded and backed by Iron Path Capital, a private equity firm specializing in lower-middle market investments across the specialty industrial and healthcare sectors.

Company Information

Company

PureTech Scientific

Location

Belle, West Virginia, United States

About

PureTech Scientific, formerly Chemours Glycolic Acid Division, is the global leader in organic synthesis of ultra-high purity alpha hydroxy acids for the Life Sciences and Specialty Chemical industries, and the sole manufacturer in the Americas. With over 85 years of operating experience and a commitment to reducing our carbon footprint, we are dedicated to world-class products, innovations, and customer support for a healthier and safer world.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed